Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure.

Journal Article (Clinical Trial;Journal Article)

Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure.

Full Text

Duke Authors

Cited Authors

  • Spence, AM; Berger, MS; Livingston, RB; Ali-Osman, F; Griffin, B

Published Date

  • February 1, 1992

Published In

Volume / Issue

  • 12 / 2

Start / End Page

  • 187 - 191

PubMed ID

  • 1560266

Pubmed Central ID

  • 1560266

International Standard Serial Number (ISSN)

  • 0167-594X

Digital Object Identifier (DOI)

  • 10.1007/BF00172671


  • eng

Conference Location

  • United States